Tuesday’s packed schedule will let attendees hear from Anders Tveteraas, international head of patient solutions and services at Novartis and Julie Anderson, principal, behavioural health s
From Akili’s transition to over-the-counter to the downfall of Pear Therapeutics, it’s been an exciting time lately in the world of digital therapeutics.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh